Semaglutide is currently being investigated in two large phase III clinical trial programs for treating obesity: the STEP program, which aims to obtain regulatory approval for semaglutide as an anti-obesity drug and is evaluating cardiovascular outcomes in 17,500 patients
Forecasting Methods Time-series modelling S-curve and diffusion models (for emerging technologies) Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes) Price elasticity models Market maturity and lifecycle-based projections Scenario Analysis Given inherent uncertainties, three scenarios were constructed: Base-Case Scenario: Expected trajectory under current conditions Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds Conservative Scenario: Slow adoption, regulatory delays, economic constraints Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption
The biorepository provided questionnaire data and milk samples of eight individuals
Retatrutide is currently in Phase 3 clinical trials, which means it successfully passed Phase 1 (safety in healthy volunteers) and Phase 2 (efficacy and safety in target population)
